These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 33555095)

  • 1. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.
    Mody K; Kasi PM; Yang J; Surapaneni PK; Bekaii-Saab T; Ahn DH; Mahipal A; Sonbol MB; Starr JS; Roberts A; Nagy R; Lanman R; Borad MJ
    JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
    Chung C; Galvin R; Achenbach E; Dziadkowiec O; Sen S
    Oncology (Williston Park); 2021 Dec; 35(12):794-803. PubMed ID: 35089001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
    Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
    Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
    Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
    Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.
    Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O
    Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
    Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T
    Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.